The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer

Launched by THOMAS JEFFERSON UNIVERSITY · Aug 15, 2022

Keywords

ClinConnect Summary

This clinical trial is studying two different surgical methods used during lung cancer surgery to see which one better reduces tiny pieces of tumor DNA that can enter the bloodstream. These DNA pieces, called circulating tumor DNA (ctDNA), might help doctors understand if cancer cells spread during surgery. The two methods involve which blood vessel is tied off first during lung surgery: either the vein or the artery. Researchers want to find out if tying off the vein first lowers the chance of tumor cells spreading and if this could help improve long-term survival for patients with early to mid-stage non-small cell lung cancer (stages I to III).

People who may be eligible for this study are adults 18 years or older who have been diagnosed or are suspected to have stage I to III non-small cell lung cancer and are scheduled for lung surgery as part of their regular treatment. Patients who had other cancers recently, received chemotherapy or radiation before surgery, or had blood transfusions around the time of surgery cannot join. If you participate, your surgeon will use one of the two surgical methods during your lung operation, and the researchers will collect blood samples to measure the tumor DNA levels. This study is currently looking for participants and aims to help improve lung cancer surgery in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Any patients 18 years of age or older with confirmed or suspected early-stage (stage I-III) NSCLC
• • Eligible and scheduled for surgical anatomic lung resection (e.g. lobectomy or segmentectomy) as routine clinical care for their disease
• Exclusion Criteria:
• • Previous cancer diagnosis within 5 years (except ductal carcinoma in situ \[DCIS\] of the breast, superficial bladder cancer, non-melanoma skin primary, other malignancy that does not require treatment).
• • Preoperative chemotherapy, immunotherapy, or radiation therapy
• • Receipt of perioperative blood transfusion